Highlights Hoth Therapeutics, Inc.

Equities

HOTH

US44148G2049

Market Closed - Nasdaq Other stock markets 21:30:00 24/06/2024 BST			5-day change	1st Jan Change
0.9302 ^USD	+0.67%		+0.65%	-35.40%

05-14	Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-28	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	03-19	CI
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments	01-18	DJ
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients	01-18	CI
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami	12-27	CI
Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies	12-05	CI
Hoth Therapeutics to Advance HT-KIT After Positive Feedback From FDA	11-14	MT
Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	11-14	CI
Hoth Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients	02/10/23	CI
Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia	13/09/23	CI
Hoth Therapeutics Seeks FDA Meeting to Discuss HT-KIT Cancer Drug Program	11/09/23	MT
Hoth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	25/07/23	CI
Hoth Therapeutics Says FDA Approved Protocol Change in Trial of Treatment for Cancer Therapy-Induced Skin Disorders	19/07/23	MT
Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic	19/07/23	CI
Fed Rate Decision Eyed Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	14/06/23	MT
Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site	14/06/23	CI
Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hoth Therapeutics, Inc.

Equities

HOTH

US44148G2049

Highlights

Filters